退行性星細胞瘤市場規模、佔有率和成長分析（按級別、分子生物標記、治療類型、年齡層、治療線和地區分類）—2026-2033年產業預測

預計到 2024 年，全球退行性星細胞瘤市場規模將達到 23.9 億美元，到 2025 年將達到 25.9 億美元，到 2033 年將達到 50.2 億美元，預測期（2026-2033 年）的複合年成長率為 8.6%。

全球間退行性星細胞瘤市場正經歷顯著成長，這主要得益於高級別膠質瘤發病率的上升、精準醫療的日益普及以及免疫腫瘤學和標靶治療的進步。主要企業正致力於開展旨在提高存活率和降低復發率的臨床試驗。此外，早期診斷的趨勢以及人們對分子診斷認知的不斷提高也進一步推動了市場擴張。醫療機構對各種治療方法的支持和研究經費的投入正在推動創新。然而，高昂的治療費用、有限的根治性治療方法選擇以及腦腫瘤治療的複雜性等挑戰正在阻礙市場發展。此外，低收入地區診斷延遲以及新治療方法的監管障礙等因素也限制了新治療方法的廣泛應用和長期數據的收集。

全球間退行性星細胞瘤市場促進因素

全球間退行性星細胞瘤市場正受到分子診斷技術和生物標記指導治療策略日益廣泛的應用的顯著影響。這種向精準腫瘤學的轉變使醫療服務提供者能夠根據腫瘤的基因譜制定個人化治療方法，從而在提高療效的同時最大限度地減少副作用。此外，人們對癌症治療方案的認知不斷提高，以及基因組檢測的普及，正在推動精準腫瘤學快速融入先進的醫療保健系統。治療調查方法的這一發展有望徹底改變患者照護，並強調以個人化方法滿足每位患者的個別需求。

全球間退行性星細胞瘤市場的限制因素

包括免疫療法和先進基因組檢測在內的創新療法費用高昂，給患者，特別是中低收入國家的患者，帶來了巨大的就醫障礙。這些挑戰源自於保險覆蓋範圍的不均衡和高額的自付費用，阻礙了患者獲得最有效的治療。因此，間退行性星細胞瘤瘤患者在治療機會上面臨不平等，常常延誤就醫。這些經濟限制加劇了醫療保健的不平等，使患者無法及時獲得有效的治療性介入，而這些干預本可以改善臨床療效和生活品質。因此，消除這些經濟障礙對於改善患者獲得最合適治療方案的機會至關重要。

全球間退行性星細胞瘤市場趨勢

全球間退行性星細胞瘤市場正經歷將分子診斷融入臨床實踐的顯著趨勢，徹底改變了治療調查方法。先進的基因譜分析技術，特別是針對IDH、EGFR和TERT突變的檢測，正在拓展個人化治療方案，並最佳化患者預後。這一趨勢不僅提高了診斷的特異性，也細化了患者分型，從而實現更具針對性和有效性的干涉。此外，分子診斷技術正在促進針對特定突變的標靶治療的開發，進一步推動該領域的研究和發展。因此，在精準醫療的推動下，該市場可望實現成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球間退行性星細胞瘤市場規模（依等級分類）及複合年成長率（2026-2033 年）

• 三年級
• 四級

全球退行性星細胞瘤市場規模（按分子生物標記和複合年成長率分類）（2026-2033 年）

• IDH突變
• IDH野生型
• TERT突變
• EGFR突變

全球間退行性星細胞瘤市場規模（按治療類型和複合年成長率分類）（2026-2033 年）

• 外科手術
• 放射線治療
• 化療
• 免疫療法
• 標靶治療

全球退行性星細胞瘤市場規模：依年齡層和複合年成長率分類（2026-2033 年）

• 兒童
• 成人

全球退行性星細胞瘤市場規模：依治療線和複合年成長率分類（2026-2033 年）

• 主要治療
• 二級治療
• 三級治療

全球退行性星細胞瘤市場規模：按地區和複合年成長率分類（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Merck & Co., Inc.（United States）
• Novartis International AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Pfizer Inc.（United States）
• Amgen Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（United States）
• Orbus Therapeutics Inc.（United States）
• Cothera Bioscience Pty Ltd（Australia）
• Jazz Pharmaceuticals（Ireland）
• Chimerix（United States）
• Candel Therapeutics, Inc.（United States）
• Isarna Therapeutics GmbH（Germany）
• Boehringer Ingelheim International GmbH（Germany）
• Celldex Therapeutics Inc.（United States）
• Bristol-Myers Squibb Co.（United States）
• Servier Pharmaceuticals LLC（France）
• Cipla Limited（India）
• Novocure Ltd.（Israel）
• Kazia Therapeutics（Australia）

結論與建議

Global Anaplastic Astrocytoma Market size was valued at USD 2.39 Billion in 2024 and is poised to grow from USD 2.59 Billion in 2025 to USD 5.02 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The global anaplastic astrocytoma market is experiencing significant growth driven by an increasing prevalence of high-grade gliomas, a heightened emphasis on precision medicine, and advancements in immuno-oncology and targeted therapies. Key industry players are focusing on clinical trials aimed at enhancing survival rates while minimizing recurrence. Additionally, the trend towards early diagnosis and heightened awareness of molecular diagnostics is further propelling market expansion. Support from healthcare institutions and research funding across various treatment approaches fosters innovation. However, challenges such as high treatment costs, the limited availability of curative options, and the complexity involved in brain tumor care impede market progress. Furthermore, barriers like delayed diagnosis in lower-income regions and regulatory hurdles for new therapies restrict broader adoption and long-term data on newer treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anaplastic Astrocytoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anaplastic Astrocytoma Market Segments Analysis

Global Anaplastic Astrocytoma Market is segmented by Grade, Molecular Biomass, Treatment Type, Age Group, Line Of Therapy and region. Based on Grade, the market is segmented into Grade III and Grade IV. Based on Molecular Biomass, the market is segmented into IDH-Mutant, IDH-Wildtype, TERT-Mutant and EGFR-Mutant. Based on Treatment Type, the market is segmented into Surgery, Radiotherapy, Chemotherapy, Immunotherapy and Targeted Therapy. Based on Age Group, the market is segmented into Pediatric and Adult. Based on Line Of Therapy, the market is segmented into First-Line, Second-Line and Third-Line And Beyond. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anaplastic Astrocytoma Market

The global anaplastic astrocytoma market is being significantly influenced by the rising utilization of molecular diagnostics and biomarker-oriented treatment strategies. This shift towards precision oncology enables healthcare providers to tailor therapies according to the genetic profile of tumors, ultimately enhancing treatment effectiveness while minimizing side effects. Furthermore, the growing awareness surrounding cancer treatment options, alongside an increase in genomic testing, is facilitating the rapid integration of precision oncology into advanced healthcare systems. This evolution in treatment methodologies is poised to transform patient care, emphasizing personalized approaches that cater to individual patient needs.

Restraints in the Global Anaplastic Astrocytoma Market

The high costs associated with innovative treatments, including immunotherapy and advanced genomic testing, pose a significant barrier to patients, particularly in low- and middle-income nations. This challenge arises from inconsistent insurance coverage and substantial out-of-pocket expenses that hinder access to the most effective therapies. Consequently, patients diagnosed with anaplastic astrocytoma often experience disparities in treatment availability, leading to delays in receiving necessary care. Such financial constraints contribute to inequities in healthcare, preventing individuals from obtaining timely and effective interventions that could improve their clinical outcomes and overall quality of life. Thus, addressing these economic barriers is critical to enhancing patient access to optimal treatment options.

Market Trends of the Global Anaplastic Astrocytoma Market

The Global Anaplastic Astrocytoma market is witnessing a significant trend toward the incorporation of molecular diagnostics into clinical practice, which is revolutionizing treatment methodologies. The adoption of advanced genetic profiling techniques, particularly focusing on IDH, EGFR, and TERT mutations, is enhancing personalized therapy options and optimizing patient outcomes. This trend not only increases diagnostic specificity but also refines patient stratification, allowing for more targeted and effective interventions. Furthermore, molecular diagnostics are facilitating the development of mutation-targeted therapies, propelling research and innovation in the field. As a result, the market is poised for growth driven by these advancements in precision medicine.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anaplastic Astrocytoma Market Size by Grade & CAGR (2026-2033)

• Market Overview
• Grade III
• Grade IV

Global Anaplastic Astrocytoma Market Size by Molecular Biomass & CAGR (2026-2033)

• Market Overview
• IDH-Mutant
• IDH-Wildtype
• TERT-Mutant
• EGFR-Mutant

Global Anaplastic Astrocytoma Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Surgery
• Radiotherapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy

Global Anaplastic Astrocytoma Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult

Global Anaplastic Astrocytoma Market Size by Line Of Therapy & CAGR (2026-2033)

• Market Overview
• First-Line
• Second-Line
• Third-Line And Beyond

Global Anaplastic Astrocytoma Market Size & CAGR (2026-2033)

• North America (Grade, Molecular Biomass, Treatment Type, Age Group, Line Of Therapy)
  • US
  • Canada
• Europe (Grade, Molecular Biomass, Treatment Type, Age Group, Line Of Therapy)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Grade, Molecular Biomass, Treatment Type, Age Group, Line Of Therapy)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Grade, Molecular Biomass, Treatment Type, Age Group, Line Of Therapy)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Grade, Molecular Biomass, Treatment Type, Age Group, Line Of Therapy)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orbus Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cothera Bioscience Pty Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chimerix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Candel Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Isarna Therapeutics GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Pharmaceuticals LLC (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novocure Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kazia Therapeutics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations